Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
Interest Income Expense
Innovent Biologics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Innovent Biologics Inc
HKEX:1801
|
Interest Income Expense
¥445.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Interest Income Expense
-¥59.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Interest Income Expense
¥217.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
134%
|
CAGR 10-Years
N/A
|
|
S
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Interest Income Expense
¥25.8m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Interest Income Expense
-¥33.6m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Interest Income Expense
¥100.8m
|
CAGR 3-Years
126%
|
CAGR 5-Years
96%
|
CAGR 10-Years
N/A
|
See Also
What is Innovent Biologics Inc's Interest Income Expense?
Interest Income Expense
445.8m
CNY
Based on the financial report for Dec 31, 2023, Innovent Biologics Inc's Interest Income Expense amounts to 445.8m CNY.
What is Innovent Biologics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
84%
Over the last year, the Interest Income Expense growth was -47%.